We are looking for a candidate to prepare a doctoral thesis with the possibility of obtaining funding by national or regional PhD grants. The candidate must have obtained a bachelor’s degree after 1st January 2019, with a minimum average mark of 8.05. The successful candidate will join the Digestive Pharmacology and Inflammation Research Unit (more information at https://www.farmacologiavalencia.es/en/ ), in the Department of Pharmacology, in the Faculty of Medicine and Dentistry of the University of Valencia, in the research lines headed by Prof. Ángeles Álvarez Ribelles. Our research focuses on the toxic cardiovascular effect of new antiretroviral drugs. Those interested should send their complete CV and academic record with their […]
Happy to announce that our colleague Ana Blas García has recently been appointed Permanent Professor of the Department of Physiology at the University of Valencia. Congratulate Ana on Facebook
CPI-23-279 POSITION Name: CPI-23-279 Group: A Subgroup: A1 Category: Researcher in Training Project: «Las células estrelladas hepáticas como base para nuevas estrategias terapéuticas en la fibrosis hepática. (CIGRIS/2022/133), CPI-23-279». Research Project Manager: NADEZDA APOSTOLOVA ATANASOVSKA CALL DOGV Publication Date: 26-05-2023 DOGV Publication URL No. of posts announced: 1 APPLICATION FORMS Submission deadline: Del 29 de maig al 9 de juny de 2023 Electronic application
Organized by the University of Valencia, sponsored by CIBEREHD and FISABIO, and endorsed by major international (EASL, ECCO) and Spanish societies in the field, the workshop is an initiative to bring together basic scientists and clinical experts to share their perspectives about these medical conditions, which constitute a global health problem. The programme will focus on the molecular mechanisms involved in the different types of fibrosis, particularly that found in the gut and liver, with an emphasis on aspects that are common to different organs. In this way, the workshop aims to explore avenues that might lead to an improvement of current therapies and the discovery of new pharmacological approaches. […]
Well-attended and highly interesting conference “ADVANCES IN COMPLICATED IBD”, organized in collaboration with INCLIVA (Department of Digestive Medicine de Medicine). With speakers Dolores Barrachina (Universitat de Valencia), Yamile Zabana (Hospital Universitari Mútua Terrassa) and Marc Ferrante (University Hospitals Leuven, Belguim), y moderators Maia Bosca (Hospital Clínico de Valencia) and Pilar Noos (Hospital Universitario La Fe). Co-financed with our PROMETEO grant CIPROM2021/044. Download program
We wish our colleague Cristina Bauset a productive and happy stay in Dublin, at the Conway Institute of Biomolecular and Biomedical Research, University College Dublin, where she will be under the supervision of Dr. Mario Manresa. During her stay, Cristina will carry out research to identify the fibroblast-related mediators and molecular mechanisms involved in the development of intestinal fibrosis in IBD. Congratulate Dolo on Facebook!
In our article published recentlyin the British Journal of Pharmacology, “Abacavir causes leukocyte/platelet crosstalk by neutrophil P2X7 receptor release of sLOX” we analyze the role of neutrophils–and specifically the secretomereleased by abacavir-treatedneutrophils – in the platelet activation that precedes thrombosis. We have observed that neutrophils are target cells in abacavir-induced thrombosis and that sLOX-1 could be the missing link in abacavir-associated cardiovascular risk.
Congratulate Dolo on Facebook!
Congratulate Sara on Facebook!
Our group has been recognized as a research group of excellence for the fourth consecutive time by the Department of Education, Culture and Sports (Conselleria d’Educació, Cultura i Esport ) of the Valencian regional government (Generalitat Valenciana) as part of its Prometeo programme for research groups of excellence. We have received a 4-year grant for the project “Pharmacology of the hepato-gastrointestinal tract: analysis of cellular and molecular targets for the treatment of fibrosis”. Celebrate with us on Facebook!
